| Patient | Hatshepsut |
|---|---|
| Date of birth | 1978-02-10 |
| Identifiers | MRN HR-AC006-SYN; SSN (made up) 000-06-9440 |
| Document date | 2026-07-21 |
| Author | Amunet Okafor-Harrington, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fourteen-week review: A1c, lipids, weight, periodontal therapy, knees, and screening results. [S]
Ms. Hatshepsut returns fourteen weeks after diabetes was found. She has taken semaglutide 0.5 mg weekly for three weeks, with mild fullness after large meals and no vomiting, with metformin 1000 mg and atorvastatin 20 mg each evening. She finished scaling and root planing six weeks ago; her gums bleed less. Her screening mammogram last week was normal, and the HPV test, the fecal immunochemical test, and the HIV and hepatitis tests were negative. She walks about 120 minutes a week and climbs the stairs at the sites with less knee pain. [S]
| Element | Detail |
|---|---|
| Medicines | Semaglutide 0.5 mg weekly, metformin 1000 mg, atorvastatin 20 mg |
| Gums | Scaling and root planing completed; bleeding less |
| Screening | Mammogram normal; HPV, FIT, HIV and hepatitis tests negative |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight falling slowly |
| Gastrointestinal | Positive | Mild fullness after large meals; no vomiting or abdominal pain |
| Musculoskeletal | Positive | Knee pain on stairs, much less than before; no muscle aches on the statin |
| Psychiatric | Negative | Mood good |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ibuprofen 400 mg oral tablet, one tablet by mouth every six hours as needed for dental pain, with food, for up to one week | One tablet every six hours as needed, with food; no more than four a day | Oral route | 2026-04-14 to 2026-04-22 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1 g) by mouth every six hours as needed for dental pain, alternating with ibuprofen, no more than 3 g a day, for up to one week | Two tablets every six hours as needed; no more than six a day | Oral route | 2026-04-14 to 2026-04-22 | completed | S |
| Metformin extended-release 500 mg tablet, one tablet with the evening meal for one week, then two tablets (1000 mg) with the evening meal | One tablet with the evening meal for a week, then two | Oral route | 2026-04-14 | active | S |
| Diclofenac sodium 1% gel, 4 g to each painful knee up to four times a day as needed | 4 g to each knee up to four times a day as needed | Topical route | 2026-04-14 | active | S |
| Chlorhexidine gluconate 0.12% oral rinse, 15 mL swished for 30 seconds and spat out twice daily for two weeks after the extraction | 15 mL rinse twice daily for two weeks | Oral route | 2026-04-15 to 2026-04-29 | completed | S |
| Semaglutide 0.25 mg subcutaneous injection once weekly (starting dose, planned for four weeks) | 0.25 mg once weekly | Subcutaneous route | 2026-05-26 to 2026-06-30 | completed | S |
| Semaglutide 0.5 mg subcutaneous injection once weekly (maintenance dose for now) | 0.5 mg once weekly | Subcutaneous route | 2026-06-30 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-05-26 | active | S |
| Nitrofurantoin monohydrate/macrocrystals 100 mg capsule, one capsule by mouth twice daily with food for five days | One capsule twice daily with food for five days | Oral route | 2026-06-23 to 2026-06-28 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-21 | Body height | 160 | cm | S |
| 2026-07-21 | Body weight | 88.6 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 34.6 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 74 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.6 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-21 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.6 | % | Below 5.7% is normal; 6.5% or more is diabetes; goal below 7% for most adults with diabetes | High | S |
| 2026-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 152 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=50 mg/dL | Low | S |
| 2026-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 76 | mg/dL | Goal below 100 mg/dL in diabetes, below 70 mg/dL at higher risk | Normal | S |
| 2026-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-35 U/L | Normal | S |
| 2026-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 88.6 kg, BMI 34.6; blood pressure 120/76, pulse 74 |
| Mouth | Gums pinker, less calculus |
| Knees | Crepitus; no effusion |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Painful swelling of the left lower jaw for four days, after a throbbing toothache for three weeks under a broken lower left molar; low-grade temperature, no trismus, no swelling of the floor of the mouth or neck; dental abscess suspected | resolved | confirmed | R68.84 | S — Synthetic presenting concern at the index visit, superseded by the dental diagnosis the next day. It echoes the dental disease reported on the mummy identified as hers (R, after the index date), without linking to it. |
| Acute periapical abscess of the lower left first molar (tooth 19), non-restorable, with a localized buccal vestibular swelling and no spread to fascial spaces; drained and extracted | resolved | confirmed | K04.7 | S — Synthetic modern diagnosis; no historical claim is made. |
| Type 2 diabetes found on screening (hemoglobin A1c 7.6% with a random glucose of 212 mg/dL from the same sample), with thirst and waking at night to pass urine; normal kidney function and urine albumin | active | confirmed | E11.65 | S — Synthetic screening finding at intake; not linked to the disputed claim of diabetes on the mummy (R). |
| Obesity, class 2 (BMI 36.3), with type 2 diabetes and knee osteoarthritis; she wants to feel stronger and move more easily | active | confirmed | E66.812 | S — Synthetic finding at intake, recorded in person-first language. |
| Primary osteoarthritis of both knees: pain on stairs and after standing, morning stiffness under 30 minutes, crepitus, no effusion; a clinical diagnosis without imaging | active | confirmed | M17.0 | S — Synthetic finding at intake; not linked to the osteoarthritis reported on the mummy (R). |
| Periodontitis, generalized, stage III, grade C (bone loss to the middle third of the roots, two molars lost earlier to gum disease, and A1c above 7% as a grade modifier) | active | confirmed | K05.323 | S — Synthetic finding at the dental consultation. |
| Acute uncomplicated cystitis (dysuria and frequency for two days, urine dipstick positive for leukocyte esterase and nitrite, no fever or flank pain); urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months until at goal or after a change in therapy, then every six months | Completed today | 6.6%, down from 7.6% |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 120/76 |
| Examination | Weight and BMI, recorded with her permission | Every visit | Completed today | 88.6 kg, BMI 34.6; down 5% since intake |
| Medication safety | Metformin: dose, tolerance and sick-day rules | Every visit | Completed today | 1000 mg tolerated |
| Medication safety | GLP-1 receptor agonist: dose, nausea, warning signs | Every visit | Completed today | 0.5 mg for three weeks; mild fullness only; no pancreatitis or gallbladder symptoms |
| Laboratory | Lipid panel and ALT on a statin | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 76 mg/dL, HDL 48, triglycerides 140, total 152; ALT 27 U/L |
| Laboratory | Urine albumin-to-creatinine ratio and eGFR | Yearly | Up to date | Normal at intake; next in nine months |
| Examination | Comprehensive foot examination | Yearly | Up to date | Normal at the six-week visit |
| Imaging | Diabetic eye screening | Every one to two years without retinopathy | Up to date | No retinopathy at the six-week visit |
| Survey | Depression screen (PHQ-9) | At diagnosis and at least yearly | Completed today | PHQ-9 2 |
| Survey | Diabetes distress screen | At diagnosis and at least yearly | Deferred | Missed: the CMID diabetes monograph calls for a diabetes distress screen at diagnosis and yearly, and none was done at intake or since. Judging by her low PHQ-9 and GAD-7 scores and her engagement, no harm resulted. Corrective action: a two-item diabetes distress screen at the next visit, added to the diabetes visit template |
| Self-management | Diabetes self-management education and nutrition therapy | At diagnosis, then yearly | Completed today | All four sessions completed |
| Examination | Dental and periodontal care | Periodontal maintenance every three months | Completed today | Scaling and root planing completed six weeks ago; maintenance booked |
| Examination | Knee pain and function | Every visit | Completed today | Less pain on stairs |
| Medication safety | Hepatitis B vaccine, dose 2 | At least four weeks after dose 1 | Due | Dose 1 three weeks ago; dose 2 at a nurse visit next week |
Goal progress:
Guideline basis: Standards of Care in Diabetes—2026 (Section 2, Diagnosis and Classification of Diabetes; Section 9, Pharmacologic Approaches to Glycemic Treatment) (2026); Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (Section 8) (2026); Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (Section 10) (2026); Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology (2018); 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, rheumatoid arthritis and osteoarthritis, and hyperlipidemia monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Review in three months with A1c; periodontal maintenance every three months; second hepatitis B dose next week; influenza and COVID-19 vaccines in the autumn; next preventive visit in one year. [S]